Author

Azhar Ali

National University of SingaporeORCID 0000-0002-5895-9076Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1

Frequent Co-Authors

Alice ChiodiiD· 2 shared Elena LevantiniiD· 2 shared Emilia BramantiiD· 2 shared Ettore MoscaiD· 2 shared Eva Cabrera San MillániD· 2 shared Giorgia MaroniiD· 2 shared Raffaella MercatelliiD· 2 shared Arianna ConsiglioiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alice ChiodiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The two sides of resistance: aggressiveness and mitotic instability as the Achilles heel of Osimertinib-resistant NSCLC

Paolo Armanetti, Eva Cabrera San Millán, Raffaella Mercatelli, Chiara Cavallini, Alice Chiodi, Ettore Mosca, Arianna Consiglio, Nicola Losito, Luca Menichetti, Emilia Bramanti, Azhar Ali, Elena Levantini, Giorgia Maroni

This study identifies BMI1 as a driver of Osimertinib resistance in NSCLC by promoting mitotic instability and aggressiveness, and shows that targeting BMI1 with Unesbulin can suppress tumor growth.

bioRxiv · Sep 25, 2025 · PreprintCancer Biology

Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: The Pyruvate-Acetaldehyde-Acetate Pathway As a Key Driver of Resistance

Giorgia Maroni, Eva Cabrera San Millán, Raffaella Mercatelli, Alice Chiodi, Beatrice Campanella, Massimo Onor, Letizia Modeo, Giulia Braccini, Giovanni Cercignani, Azhar Ali, Ettore Mosca, Emilia Bramanti, Elena Levantini

This study identifies metabolic reprogramming in osimertinib-resistant EGFR-mutant NSCLC, highlighting the pyruvate-acetaldehyde-acetate pathway and mitochondromic alterations as key drivers of resistance.

bioRxiv · Jun 27, 2025 · PreprintCancer Biology